Drug Trial Radar · NCT03196284
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Last checked: Nov 20, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Aug 10, 2017
Primary completion
Sep 19, 2018
Study completion Jan 31, 2020
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.
Conditions
- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors
Interventions
ConcizumabDrug
A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
Eptacog alfaDrug
A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Bleeding EpisodesTime frame: During at least 24 weeks from treatment onset (week 0)
Locations
22 sites in 14 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Indianapolis, Indiana
Novo Nordisk Investigational Site
Iowa City, Iowa
Novo Nordisk Investigational Site
Vienna, Austria
Novo Nordisk Investigational Site
Toronto, Ontario, Canada
Novo Nordisk Investigational Site
Zagreb, Croatia
Novo Nordisk Investigational Site
Århus N, Denmark
Novo Nordisk Investigational Site
Athens, Greece
Novo Nordisk Investigational Site
Tel HaShomer, Israel
Novo Nordisk Investigational Site
Florence, Italy
Novo Nordisk Investigational Site
Milan, Italy
Novo Nordisk Investigational Site
Aichi, Japan
Novo Nordisk Investigational Site
Nara, Japan
Novo Nordisk Investigational Site
Tokyo, Japan
Novo Nordisk Investigational Site
Georgetown, Penang, Malaysia
Novo Nordisk Investigational Site
Kota Kinabalu, Malaysia
Novo Nordisk Investigational Site
Madrid, Spain
Novo Nordisk Investigational Site
Seville, Spain
Novo Nordisk Investigational Site
Solna, Sweden
Novo Nordisk Investigational Site
Lviv, Ukraine
Novo Nordisk Investigational Site
London, United Kingdom
Novo Nordisk Investigational Site
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.